Article    Table of Contents                    Full Text of this article Free    Figures/Tables List  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search                            Get Permissions  Google Scholar    Search for Related Content  PubMed Articles in PubMed by Author:    Garnick, M. B.    Related Articles in PubMed    PubMed Citation    PubMed

REVIEW

Prostate Cancer: Screening, Diagnosis, and Management

Marc B. Garnick

15 May 1993 | Volume 118 Issue 10 | Pages 804-818

Objective: To provide physicians with a review of diagnosis, screening, staging evaluation, treatment options, prognosis, psychosocial issues, economic considerations, and future research directions in the management of patients with all stages of prostate cancer.

Data Sources: A MEDLINE search of articles relating to the diagnosis, staging, screening, surgery, radiation therapy, medical management, and research in prostate cancer. Emphasis on information reported from government- and nongovernment-sponsored large cooperative trials, consensus development conferences, and proceedings of prostate cancer organ site workshops.

Study Selection: Results of randomized treatment trials and consensus summary statements are reported where long-term results (> 5 years follow-up) are available for localized prostate cancer treatment and where survival outcomes are available for metastatic disease treatment.

Data Synthesis: Both qualitative and quantitative data are reported. Information on staging, management, and prognosis of localized prostate cancer is based on studies that are predominantly nonrandomized, include heterogeneous patient groups, and often use differing outcome measures. Information on management of metastatic prostate cancer is more quantitative and includes side effects of treatment and survival results obtained from randomized, prospective, multi-institutional studies.

Conclusions: Despite the increase in prostate cancer incidence and detection, substantial controversy still exists about the advisability and effectiveness of screening programs, the most appropriate staging evaluation, and the optimal management of patients with all stages of prostate cancer. Although randomized, prospective studies attempt to address some of these issues, physicians must appreciate inherent ambiguities involved in recommending staging and treatment choices.

Author and Article Information

From Dana-Farber Cancer Institute, Boston, Massachusetts, and Genetics Institute, Inc., Cambridge, Massachusetts.
Requests for Reprints: Marc B. Garnick, MD, Genetics Institute, 87 Cambridge Park Dr., Cambridge, MA 02140.

This article has been cited by other articles:

				G. CARRUBA Estrogens and Mechanisms of Prostate Cancer Progression Ann. N.Y. Acad. Sci., November 1, 2006; 1089(1): 201 - 217. [Abstract] [Full Text] [PDF]

				A. Broom Medical specialists' accounts of the impact of the Internet on the doctor/patient relationship Health (London) , July 1, 2005; 9(3): 319 - 338. [Abstract] [PDF]

				A. Broom The eMale: Prostate cancer, masculinity and online support as a challenge to medical expertise Journal of Sociology, March 1, 2005; 41(1): 87 - 104. [Abstract] [PDF]

				A. Broom Virtually He@lthy: The Impact of Internet Use on Disease Experience and the Doctor-Patient Relationship Qual Health Res, March 1, 2005; 15(3): 325 - 345. [Abstract] [PDF]

				Curcumin Derivatives: Potential for Prostate Cancer Management: ADDANKI P. KUMAR, GRETCHEN E. GARCIA, RITA GHOSH, RAJENDRAN V. RAJNARAYANAN,1 WILLIAM L. ALWORTH,1 AND THOMAS J. SLAGA, Center for Cancer Causation and Prevention, AMC Cancer Research Center and University of Colorado Comprehensive Cancer Center, Denver, Colorado 80214; 1 Department of Chemistry, Tulane University, New Orleans, Louisiana 70118 Toxicol Pathol, January 1, 2004; 32(1): 161 - 163. [PDF]

				L. Navon and A. Morag Advanced Prostate Cancer Patients' Ways of Coping with the Hormonal Therapy's Effect on Body, Sexuality, and Spousal Ties Qual Health Res, December 1, 2003; 13(10): 1378 - 1392. [Abstract] [PDF]

				P. A. Godley, A. P. Schenck, M. A. Amamoo, V. J. Schoenbach, S. Peacock, M. Manning, M. Symons, and J. A. Talcott Racial Differences in Mortality Among Medicare Recipients After Treatment for Localized Prostate Cancer J Natl Cancer Inst, November 19, 2003; 95(22): 1702 - 1710. [Abstract] [Full Text] [PDF]

				H. P. Koeffler Peroxisome Proliferator-activated Receptor {gamma} and Cancers Clin. Cancer Res., January 1, 2003; 9(1): 1 - 9. [Abstract] [Full Text] [PDF]

				K. El-Bayoumy, J. P. Richie Jr., T. Boyiri, D. Komninou, B. Prokopczyk, N. Trushin, W. Kleinman, J. Cox, B. Pittman, and S. Colosimo Influence of Selenium-enriched Yeast Supplementation on Biomarkers of Oxidative Damage and Hormone Status in Healthy Adult Males: A Clinical Pilot Study Cancer Epidemiol. Biomarkers Prev., November 1, 2002; 11(11): 1459 - 1465. [Abstract] [Full Text] [PDF]

				S. A. Stoch, R. A. Parker, L. Chen, G. Bubley, Y.-J. Ko, A. Vincelette, and S. L. Greenspan Bone Loss in Men with Prostate Cancer Treated with Gonadotropin-Releasing Hormone Agonists J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2787 - 2791. [Abstract] [Full Text] [PDF]

				J. A. Clark, N. P. Wray, and C. M. Ashton Living With Treatment Decisions: Regrets and Quality of Life Among Men Treated for Metastatic Prostate Cancer J. Clin. Oncol., January 1, 2001; 19(1): 72 - 80. [Abstract] [Full Text] [PDF]

				E. J. Small, P. Fratesi, D. M. Reese, G. Strang, R. Laus, M. V. Peshwa, and F. H. Valone Immunotherapy of Hormone-Refractory Prostate Cancer With Antigen-Loaded Dendritic Cells J. Clin. Oncol., December 1, 2000; 18(23): 3894 - 3903. [Abstract] [Full Text] [PDF]

				E. J. Small, M. Meyer, M. E. Marshall, L. M. Reyno, F. J. Meyers, R. B. Natale, P. F. Lenehan, L. Chen, W. J. Slichenmyer, and M. Eisenberger Suramin Therapy for Patients With Symptomatic Hormone-Refractory Prostate Cancer: Results of a Randomized Phase III Trial Comparing Suramin Plus Hydrocortisone to Placebo Plus Hydrocortisone J. Clin. Oncol., April 7, 2000; 18(7): 1440 - 1450. [Abstract] [Full Text] [PDF]

				B. B. Yeap, R. G. Krueger, and P. J. Leedman Differential Posttranscriptional Regulation of Androgen Receptor Gene Expression by Androgen in Prostate and Breast Cancer Cells Endocrinology, July 1, 1999; 140(7): 3282 - 3291. [Abstract] [Full Text]

				S. Griffiths Men's health BMJ, January 13, 1996; 312(7023): 69 - 70. [Full Text]

				R. G. Badgett and R. C.S. Ho Screening for Prostate Cancer N. Engl. J. Med., January 20, 1994; 330(3): 220 - 221. [Full Text]